Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
8.03
-0.35 (-4.18%)
Feb 21, 2025, 4:00 PM EST - Market closed
Enanta Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Enanta Pharmaceuticals stock have an average target of 17.25, with a low estimate of 10 and a high estimate of 21. The average target predicts an increase of 114.82% from the current stock price of 8.03.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Enanta Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 2 | 1 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | +124.16% | Feb 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $18 | Strong Buy | Maintains | $27 → $18 | +124.16% | Dec 24, 2024 |
| Baird | Baird | Buy Maintains $26 → $20 | Buy | Maintains | $26 → $20 | +149.07% | Nov 26, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $22 → $21 | Buy | Reiterates | $22 → $21 | +161.52% | Nov 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +236.24% | Oct 10, 2024 |
Financial Forecast
Revenue This Year
63.99M
from 67.64M
Decreased by -5.39%
Revenue Next Year
52.20M
from 63.99M
Decreased by -18.42%
EPS This Year
-4.34
from -5.48
EPS Next Year
-4.71
from -4.34
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 70.9M | 73.6M | 46.1M | ||
| Avg | 64.0M | 52.2M | 38.2M | ||
| Low | 56.8M | 32.3M | 30.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.8% | 15.0% | -11.8% | ||
| Avg | -5.4% | -18.4% | -26.8% | ||
| Low | -16.0% | -49.5% | -41.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.02 | -2.61 | -1.79 | ||
| Avg | -4.34 | -4.71 | -4.51 | ||
| Low | -6.16 | -9.31 | -9.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.